ESMO: European Society for Medical Oncology

1. The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic Assessment in Metastatic Non-Seminomatous Germ Cell Tumours

   It includes age and lung metastases as additional adverse prognostic factors and uses a single cut-off of LDH at 2.5× ULN 

2. Percentage of Cancer Patients Who Are Eligible for and Respond to Genome-Targeted Therapy Modestly Increased Over Time

   A new analysis from US show that response to genome-targeted therapy increased from 2.73% in 2006 to 7.04% in 2020

3. FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer

   Evidence for efficacy and safety is based on the results from the TROPHY study

4. FDA Approves New Dosing Regimen for Cetuximab

   Approval is based on population pharmacokinetic modelling analyses

5. FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast Cancer

   Efficacy and safety were evaluated in the ASCENT study